Retinol is the most decorated molecule in skincare. It is also the one that breaks the most skin.
Used correctly, vitamin A and its derivatives do real work — they accelerate cell turnover at the surface, encourage the dermis to produce collagen, and over many months they reduce the appearance of lines and uneven tone. Used at the concentrations the industry has settled on (0.3–1% retinol, with prescription tretinoin higher still), they produce a predictable cost: photosensitivity, barrier disruption, peeling, and a period of adaptation that, for sensitive skin, can last months. For pregnant and nursing skin, the molecule is contraindicated entirely.
ETHER does not contain retinol. It contains bakuchiol, a molecule extracted from the seeds of Psoralea corylifolia, a plant that has been part of traditional Indian and Chinese medicine for longer than vitamin A has been isolated. It is not retinol, and we do not call it that.
The study that made the case
In 2019, a study was published in the British Journal of Dermatology — a journal with standards that do not accommodate cosmetic marketing. Forty-four volunteers were divided into two groups. One group applied 0.5% retinol daily for twelve weeks. The other applied 0.5% bakuchiol twice daily for the same period. Every outcome was measured by photography and scored by blind assessors — wrinkle depth, surface pigmentation, firmness, and side effects.
The result: both groups showed statistically significant improvements in wrinkle depth and hyperpigmentation. There was no meaningful difference between them. The retinol group, however, reported significantly more scaling and stinging. The bakuchiol group tolerated their routine at a rate the retinol group did not.
Bakuchiol does not chemically become retinol. It triggers comparable cellular renewal pathways without binding to retinoid receptors, without the photosensitivity, without the barrier disruption. The downstream result — renewal — is equivalent in effect. The path to it is different.
Why this matters for ETHER
We designed ETHER as the final step of the evening — an oil worn over the cream, held on the skin until sleep. The formulation choice flows from a single question: what molecule, applied nightly for months, is most likely to still be in use in year three?
Retinol, used nightly by a skin that tolerates it, is a powerful tool. Used nightly by a skin that does not tolerate it — and most skin does not, at first — it produces enough friction that the user abandons it within the season. The molecule that works is the one still in the routine at month nine.
Bakuchiol is stable in oil, which allows us to build ETHER without the preservation system that water-based retinol formulas require. It is compatible with the other steps of the evening — REVEAL on treatment nights, the peptide concentrate, the ceramide cream. It does not require a sunscreen-only routine the following morning.
The 1.5% concentration
We land at 1.5% for a reason. The clinical studies using bakuchiol at meaningful outcome levels land between 0.5% and 2%. At 0.5% the effect is gentle and takes longer. At 2% the molecule begins to show its own signs of sensitivity on reactive skin. 1.5% is the concentration at which the effect is consistent and the tolerance is broad.
It is calibrated for nightly use. It is effective at every age. It is a gentle molecule, traditionally also used in sensitive phases of life. Stable in oil.
We will not claim it is retinol. We will say that, for the work retinol is asked to do, bakuchiol does the same job without the price.